Harrisvaccines has been named to provide RNA process development for a trivalent vaccine against the hemorrhagic fever-causing filoviruses known as Ebola virus and Marburg virus.
The project is funded by a $15 million contract overseen by the Chemical Biological Medical Systems-Joint Vaccine Acquisition Program, which are responsible for developing, acquiring and stockpiling Food and Drug Administration-approved vaccines to protect against biological weapons. “The opportunity to be involved in a project this significant to human health is a milestone for Harrisvaccines,” said Dr. D.L. “Hank” Harris, founder and president of Harrisvaccines. “Our ability to create efficacious vaccines and produce them rapidly has put Harrisvaccines in a position to apply breakthrough RNA technology to both the human and animal vaccine worlds.”